Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKARDI AI Technologies s.r.o.

About this trial

The goal of this clinical trial is to evaluate the safety and efficacy of medical device Kardi Ai, an ECG telemetry monitoring device in adult population.

The main questions it aims to answer are:

* What is the sensitivity and specificity of Kardi Ai device for all monitored heart rythm disorders (combined) * What is the sensitivity and specificity of Kardi Ai device for each of the monitored heart rythm disorders * What is the quality of the ECG recordings

Participants will receive Kardi Ai medical device. They will use it to collect ECG recordings from at least 5 different days and in total collect records of at least 10 hours duration.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age above 18 years

Signed informed consent/willingness to cooperate

Confirmed or suspected heart rhythm disorder of a cardiac rhythm disorder

Ability to use a smartphone and mobile app Kardi Ai

Disqualifiers

Confirmed pregnancy

Allergic reactions to standard substances used in manufacture of clothing or other textiles

Superficial wound or skin irritation at the site of the chest belt attachment

Trial design

Design model

Single group

Treatments tested in this trial

  • Medical device

    Device

    Adding Kardi Ai medical device for detection of heart rythm disorders

Treatment groups

115 Participants
are divided into 1 treatment group
Group A: Group with potential heart rythm disorderExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Evaluation of sensitivity and specificity of Kardi Ai across all measurements and heart rythm disorders.

Evaluation of sensitivity and specificity of Kardi Ai across all measurements and heart rythm disorders.

Time frame
From enrollment to the end of measurements at 3 weeks

Secondary outcomes

1

Evaluation of sensitivity and specificity of Kardi Ai across all measurements for each monitored heart rythm disorders.

Evaluation of sensitivity and specificity of Kardi Ai across all measurements for each monitored heart rythm disorders.

Time frame
From enrollment to the end of measurements at 3 weeks

Other outcomes

1

Evaluation of the quality of ECG measurements

Evaluation of the quality of ECG measurements. ECG will be evaluated by physician annotator, who will adjudicate the quality of the ECG on the three point scale. 1 - excellent(above 90% QRS recognizable), 2- medium(above 70% QRS recognizable), 3 - poor(less than 70% QRS recognizable).

Time frame
From enrollment to the end of measurements at 3 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

KARDI AI Technologies s.r.o.

Lead sponsor

Fakultní nemocnice Olomouc

Collaborator

University Hospital Ostrava

Collaborator